Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole

Journal of the National Cancer Institute

Volumn 85, Issue 23, 1993, Pages 1921-1926

  Rigas, James R ^a   Francis, Prudence A ^a   Muindi, Josephia R F ^a   Kris, Mark G ^a   Huselton, Christine ^b   Degrazia, Francis ^b   Orazem, John P ^a   Young, Charles W ^a   Warrell, Raymond P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOCHROME P450 REDUCTASE; ISOTRETINOIN; KETOCONAZOLE; MITOMYCIN; RETINOIC ACID; VINBLASTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHEILITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG METABOLISM; DRUG OXIDATION; DRUG RESISTANCE; DRY SKIN; FEMALE; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERCALCEMIA; HYPERTRIGLYCERIDEMIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION;

CARCINOMA, NON-SMALL-CELL LUNG; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOLERANCE; HUMAN; KETOCONAZOLE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LUNG NEOPLASMS; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRETINOIN;

EID: 0027524546     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.23.1921     Document Type: Article

References (54)

1. Tabin CJ: Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell 66:199-217, 1991.
2. Roberts AB, Spom MB: Cellular biology and biochemistry of the retinoids. In The Retinoids (Spom MB, Roberts AB, Goodman DS, eds), 2nd ed. New York: Academic Press, 1984, pp 209-286
3. Shekelle RB, Lepper M, Liu S, et al: Dietary vitamin A and risk of cancer in the Western Electric study. Lancet 2:1186-1190, 1981
4. Byers TE, Graham S, Haughy BP, et al: Diet and lung cancer risk: findings from the Western New York diet study. Am J Epidemiol 125:351-363, 1987
5. Kark JD, Smith AH, Hames CG: Serum vitamin A (retinol) and cancer incidence in Evans County, Georgia. JNCI 66:7-16, 1981
6. Gouveia J, Mathe G, Hercend F, et al: Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet 1:710-712, 1982
7. Stinson SF, Reznik G, Donahoe R: Effect of three retinoids on tracheal carcinogenesis with A’-methyl-A’-nitrosourea in hamsters. JNCI 66:947-951, 1981
8. Hong WK, Endicott J, Itri LM: 13-cir-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
9. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993
10. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
11. Huang ME, Ye YC, Chai JR: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988
12. Castaigne S, Chomienne C, Daniel MT: AU-lrans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: 1. Clinical results. Blood 76:1704-1709, 1990
13. Warrell RP Jr, Frankel SR, Miller WH Jr, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (allmans retinoic acid). N Engl J Med324:1385-1393, 1991
14. Muindi JR, Frankel SR, Huselton C, et al: Clinical pharmacology of oral all-rranr-retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52:2138-2142, 1992
15. Roberts AB, Lamb LC, Spom MB: Metabolism of all-mans-retinoic acid hamster liver microsomes: oxidation of 4-hydroxy-to 4-keto-retinoic acid. Arch Biochem Biophys 199:374-383, 1980
16. Leo MA, lida S, Lieber CS: Retinoic acid metabolism by a system reconstituted with cytochrome P-450. Arch Biochem Biophys 234:305-312, 1984
17. Huselton CA, Fayer BE, Garland WA, et al: Quantification of endogenous retinoic acid in human plasma by liquid chromatography/mass spectrometry. In Liquid Chromato-graphy/Mass Spectrometry: Applications in Agricultural, Pharmaceutical, and Environmental Chemistry (Brown MA, ed). Washington, DC: Am Chem Soc, 1990, pp 166-178
18. Gibaldi M, Perrier D: Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982, pp 480-496
19. Muindi J, Frankel SR, Miller WH Jr, et al: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 79:299-303, 1992
20. Jetten AM, Nervi C, Vollberg TM: Control of squamous differentiation in tracheobronchial and epidermal epithelial cells: role of retinoids. Monogr Natl Cancer Inst 13:93-100, 1992
21. Brazzell RK, Colburn WA: Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review. J Am Acad Dermatol 6:643-651, 1982
22. Brazzell RK, Vane FM, Ehmann CW, et al: Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 24:695-702, 1983
23. Goodman GE, Einspahr JG, Alberts DS, et al: Pharmacokinetics of 13-c/j-retinoic acid in patients with advanced cancer. Cancer Res 42:2087-2091, 1982
24. Kerr IG, Lippman ME, Jenkins J, et al: Pharmacology of 13-c/r-retinoic acid in humans. Cancer Res 42:2069-2073, 1982
25. Adamson PC, Boylan JF, Balis FM, et al: Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res 53:472-476, 1992
26. Kelly MA, Sidell N, Haussler MR: Saturation analysis of cellular retinoid binding proteins: application to retinoic acid resistant human neuroblastoma cells and to human tumors. Biochem Cell Biol 65:163-172, 1987
27. Boylan JF, Gudas LJ: Overexpression of the cellular retinoic acid binding protein-I (CRABP-I) results in a reduction in differentiation-specific gene expression in F9 teratocarcinoma cells. J Cell Biol 112:965-979, 1991
28. Roberts AB, Frolik CA, Nichols MD, et al: Retinoid-dependent induction of the in vivo and in vitro metabolism of retinoic acid in tissues of the vitamin A-deficient hamster. J Biol Chem 254:6303-6309, 1979
29. Murray M, Cantrill E, Martini R, et al: Increased expression of cytochrome P450 I1IA2 in male rat liver after dietary vitamin A supplementation. Arch Biochem Biophys 286:618-624, 1991
30. Muindi JF, Young CW: Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 53:1226-1229, 1993
31. Kraft JC, Slikker W Jr, Bailey JR, et al: Plasma pharmacokinetics and metabolism of 13-cis-and all-rrans-retinoic acid in the cynomologus monkey and the identification of 13-cis-and all-rrans-retinoyl-b-glucuronides. A comparison to one human case study with isotretinoin. Drug Metab Dispos Biol Fate Chem 19:317-324, 1991
32. Kalin JR, Wells MJ, Hill DL: Effects of phenobarbital, 3-methylcholanthrene, and retinoid pretreatment of disposition of orally administered retinoids in mice. Drug Metab Dispos Biol Fate Chem 12:63-67, 1984
33. Williams JB, Napoli JL: Inhibition of retinoic acid metabolism by imidazole antimycotics in F9 embryonal carcinoma cells. Biochem Pharmacol 36:1386-1388, 1987
34. Van Wauwe JP, Coene MC, Goossens J, et al: Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans retinoic acid. J Pharmacol Exp Ther 245:718-722, 1988
35. Van Wauwe JP, Coene MC, Goossens J, et al: Effects of cytochrome P-450 inhibitors on the in vivo metabolism of ai\-trans retinoic acid in rats. J Pharmacol Exp Ther252:365-369, 1990
36. Capdevila J, Gil L, Orellana M, et al: Inhibitors of cytochrome P-450-dependent arachidonic acid metabolism. Arch Biochem Biophys 261:257-263, 1988
37. Fiorella PD, Napoli JL: Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli. Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. J Biol Chem 266:16572-16579, 1991
38. Boylan JF, Gudas L: The level of CRABP-I expression influences the amounts and types of all-rra/u-retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chem 267:21486-21491, 1992
39. Kellerman G, Shaw CR, Luyten-Kellerman M: Aryl hydrocarbon hydroxylase induc-ibility and bronchogenic carcinoma. N Engl J Med 289:934-937, 1973
40. Kouri RE, McKinney DE, Slomiany DJ, et al: Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed by cryopre-served lymphocytes. Cancer Res 42:5030-5037, 1992
41. Meyer UA, Zanger UM, Grant D, et al: Genetic polymorphism of drug metabolism. In Advances in Drug Research (Limited AP, ed), 19th ed. Basel: Academic Press, 1990, pp 198-227
42. Ayesh R, Idle JR, Ritchie JC, et al: Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169-170, 1984
43. Law MR, Hetzel MR, Idle JR: Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 59:686-687, 1989
44. Speirs CJ, Murray S, Davies DS, et al: Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol 29:101-109, 1990
45. Caporaso NE, Tucker MA, Hoover RN, et al: Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 82:1264-1272, 1990
46. Kato S, Shields PG, Caporaso NE, et al: Cytochrome P450UE1 genetic polymorphism, racial variation, and lung cancer risk. Cancer Res 52:6712-6715, 1992
47. Sellers TA, Bailey-Wilson JE, Elston RC, et al: Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 82:1272-1279, 1990
48. Sellers TA, Potter JD, Bailey-Wilson JE, et al: Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. Cancer Res (suppl 9) 52:2694-2697, 1992
49. Loeb LA, Ernster VL, Warner KE, et al: Smoking and lung cancer: an overview. Cancer Res 44:5940-5958, 1984
50. Wolf CR, Smith CA, Gough AC, et al: Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13:1035-1038, 1992
51. 934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3’ splice recognition site. Am J Hum Genet 47:994-1001, 1990
52. Heim M, Meyer UA: Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532, 1990
53. Daly AK, Armstrong M, Monkman SC, et al: Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1:33-41, 1991.
54. Coon MJ, Ding XX, Pemecky SJ, et al: Cytochrome P450: progress and predictions. FASEB J 6:669-673, 1992.